Crossmark

Comment on: “Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E‑Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations”

Crossref DOI link: https://doi.org/10.1007/s40261-025-01468-1

Published Online: 2025-10-28

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Watkins, Claire

del Carpio, Luis

Piulats, Josep M. https://orcid.org/0000-0002-3606-1724
License Information

Text and Data Mining valid from 2025-10-28

Version of Record valid from 2025-10-28
More Information

Article History

Accepted: 24 July 2025

First Online: 28 October 2025

Declarations

:

: This paper was supported by Immunocore Ltd.

: LdC has no conflicts of interest. JMP has participated on advisory boards for Janssen, Astellas, Roche, BMS, MSD, BeiGene, VCN, and AstraZeneca and has received research grants to their institute from BMS, Pfizer, Janssen, BeiGene, and Mirati. CW has acted in advisory roles for Celgene/Bristol Myers Squibb, Roche, Immunocore, Ascelia, Humanigen, Astellas Pharma, F2G, Amylyx, Kite/Gilead, Novo Nordisk, Neurovalens, Medical Developments International, SERVIER, and EQRx.

: For access to data underlying the analysis included in this paper, please submit a request, including purpose, data format, hypothesis, and specific rationale, to info@immunocore.com.

: Conceptualization: Claire Watkins. Writing—original draft and writing—review and editing: Claire Watkins, Luis del Carpio, and Josep Piulats. All authors read and approved the final version.

Document is current

Any future updates will be listed below